statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ADC Therapeutics Accelerates R&D with Genedata Biologics ADC Therapeutics Accelerates R&D with Genedata Biologics PR Newswire BASEL, Switzerland, April 16, 2024 Enterprise software solution...

ADC Therapeutics Accelerates R&D with Genedata Biologics

Dose escalation in Phase 1b trial completed with no dose-limiting toxicities, no or low-grade cytokine release syndrome and no immune effector cell-associated neurotoxicity syndrome across all...

ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA  in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

ADC Therapeutics SA (NYSE:ADCT - Get Free Report) saw a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 939,800 shares, a growth of 8.2...

ADC Therapeutics SA (NYSE:ADCT) Short Interest Update

ADC Therapeutics gains after data for lymphoma therapy...

ADC Therapeutics gains after data for lymphoma therapy

LAUSANNE, Switzerland, April 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company will host a virtual Research Investor Event on Tuesday, April 9, 2024...

ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024

LAUSANNE, Switzerland, April 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (the Company ) (NYSE: ADCT) today announced that the Company has made grants of options to purchase an aggregate of...

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

Guggenheim assumed coverage on shares of ADC Therapeutics (NYSE:ADCT  Free Report) in a research note published on Thursday morning, MarketBeat reports. The firm issued a buy rating and a...

ADC Therapeutics (NYSE:ADCT) Coverage Initiated by Analysts at Guggenheim

Analysts at Guggenheim initiated coverage on shares of ADC Therapeutics (NYSE:ADCT  Get Free Report) in a report issued on Thursday, Marketbeat Ratings reports. The firm set a...

ADC Therapeutics (NYSE:ADCT) Earns Buy Rating from Analysts at Guggenheim

This indicator may be signaling that ADCT's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

ADC Therapeutics SA (ADCT, $4.2) entered Downtrend as Momentum indicator drops below 0 level on Mar 25, 2024

For the last three days, A.I.dvisor has detected that ADCT's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

ADC Therapeutics SA (ADCT, $4.54) Aroon Indicator entered a Downtrend on March 22, 2024.

ADC Therapeutics SA is a clinical-stage biotechnology company. It engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.

Watchers	1,067
52-Wk Low	$0.3599
52-Wk High	$6.04

Volume	3.09M
52-Wk High	$6.04
52-Wk Low	$0.3599

Period	Estimated	Reported	Surprise	Result
Q2'24	-$0.55	--	--	N/A
Q1'24	-$0.56	-$0.56	-0.76%	MISSED
Q4'23	-$0.50	-$1.03	-105.16%	MISSED
Q3'23	-$0.63	-$0.58	8.52%	BEAT
Q2'23	-$0.70	-$0.58	17.10%	BEAT

ADCT Adc Therapeutics SA

About

Feed

News

Sentiment

Earnings

Fundamentals